Johnson & Johnson is counting on new buy Actelion’s pulmonary arterial hypertension (PAH) meds to provide a top-line boost once its $30 billion transaction closes. But one of them may
Johnson & Johnson is counting on new buy Actelion’s pulmonary arterial hypertension (PAH) meds to provide a top-line boost once its $30 billion transaction closes. But one of them may